[Therapeutic intensification and hematopoietic stem cell autotransplantation in the treatment of solid tumors in adults: principles, realization and application to the treatment of germ cell, trophoblastic, breast, ovarian and small-cell bronchial tumors. 1].

[1]  E. Shpall,et al.  High-dose therapy with autologous bone marrow transplantation for the treatment of solid tumors. , 1994, Current opinion in oncology.

[2]  J. Nemunaitis.  Use of hematopoietic growth factors in marrow transplantation. , 1994, Current opinion in oncology.

[3]  J P Pignon,et al.  Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. , 1993, The New England journal of medicine.

[4]  R. Motzer,et al.  Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. , 1993, Journal of the National Cancer Institute.

[5]  R. Simon,et al.  Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis. , 1993, Journal of the National Cancer Institute.

[6]  R. Herzig,et al.  Dose‐related cutaneous toxicities with etoposide , 1993 .

[7]  M. Marangolo,et al.  High-dose chemotherapy supported with autologous bone marrow transplantation (ABMT) in germ cell tumors: a phase two study. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  R. Motzer,et al.  High-dose chemotherapy for resistant germ cell tumors: recent advances and future directions. , 1992, Journal of the National Cancer Institute.

[9]  R. Motzer,et al.  Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers , 1992, Cancer.

[10]  W. Bensinger.  Supportive care in marrow transplantation , 1992, Current Opinion in Oncology.

[11]  G. Tricot,et al.  Long-Term Outcome of Patients with Relapsed and Refractory Germ Cell Tumors Treated with High-Dose Chemotherapy and Autologous Bone Marrow Rescue , 1992, Annals of Internal Medicine.

[12]  Lieschke Gj,et al.  Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2). , 1992, The New England journal of medicine.

[13]  A. Burgess,et al.  Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor , 1992 .

[14]  D. Trump,et al.  High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Russo,et al.  High‐dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Early intervention is better tolerated , 1992, Cancer.

[16]  S. Kaye,et al.  The changing role of surgery in metastatic non-seminomatous germ cell tumour. , 1992, British Journal of Cancer.

[17]  A. Horwich,et al.  The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  B. Malassagne,et al.  Phase I-II study of two consecutive courses of high-dose epipodophyllotoxin, ifosfamide, and carboplatin with autologous bone marrow transplantation for treatment of adult patients with solid tumors. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  G. Tricot,et al.  Salvage therapy with high‐dose chemotherapy and autologous bone marrow support in the treatment of primary nonseminomatous mediastinal germ cell tumors , 1991, Cancer.

[20]  C. Bokemeyer,et al.  Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Craig R. Nichols.  Mediastinal Germ Cell Tumors: Clinical Features and Biologic Correlates , 1991 .

[22]  G. Rosner,et al.  4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  E. Dmitrovsky,et al.  The role of ifosfamide plus cisplatin‐based chemotherapy as salvage therapy for patients with refractory germ cell tumors , 1990, Cancer.

[24]  G. Tricot,et al.  Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  C. Begg,et al.  A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  A. Elias,et al.  Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  R. Wittes,et al.  Autologous bone marrow transplantation. Current status and future directions. , 1989, Annals of internal medicine.

[28]  L. Einhorn,et al.  Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. , 1988, Annals of internal medicine.

[29]  W. M. Linehan,et al.  A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  N. Geller,et al.  Comparison of criteria for assigning germ cell tumor patients to "good risk" and "poor risk" studies. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  E. Farmer,et al.  Cutaneous pathology following etoposide therapy , 1987, Journal of cutaneous pathology.

[32]  J. Droz,et al.  Clinical pharmacology of high-dose etoposide associated with cisplatin. Pharmacokinetic and metabolic studies. , 1987, European journal of cancer & clinical oncology.

[33]  L. Einhorn,et al.  Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. , 1987, The New England journal of medicine.

[34]  N. Geller,et al.  VAB-6: an effective chemotherapy regimen for patients with germ-cell tumors. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  E. Douglass,et al.  Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  L. Einhorn,et al.  VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  L. Einhorn,et al.  Prognostic factors for favorable outcome in disseminated germ cell tumors. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  L. Einhorn,et al.  Ifosfamide in refractory male germ cell tumors. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Y. Ostchega,et al.  High dose cisplatin and high dose carboplatin in refractory ovarian cancer. , 1985, Cancer treatment reviews.

[40]  N. Martini,et al.  The results of chemotherapy for extragonadal germ-cell tumors in the cisplatin era: the Memorial Sloan-Kettering Cancer Center experience (1975 to 1982). , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  J. Hainsworth,et al.  Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin: results of a Southeastern Cancer Study Group trial. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  R. Stahel,et al.  Detection of bone marrow metastasis in small-cell lung cancer by monoclonal antibody. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  M. Varini,et al.  Ifosfamide--pharmacology, safety and therapeutic potential. , 1985, Cancer treatment reviews.

[44]  G. Bosl,et al.  Role of etoposide-based chemotherapy in the treatment of patients with refractory or relapsing germ cell tumors. , 1985, The American journal of medicine.

[45]  S. Seeber,et al.  Ifosfamide in combination chemotherapy for sarcomas and testicular carcinomas. , 1983, Cancer treatment reviews.

[46]  J. Hainsworth,et al.  Advanced extragonadal germ-cell tumors. Successful treatment with combination chemotherapy. , 1982, Annals of internal medicine.

[47]  S. Seeber,et al.  Etoposide and etoposide-ifosfamide therapy for refractory testicular tumors. , 1982, Cancer treatment reviews.

[48]  L. Einhorn,et al.  Etoposide salvage therapy for refractory germ cell tumors: an update. , 1982, Cancer treatment reviews.

[49]  E. Frei,et al.  Dose: a critical factor in cancer chemotherapy. , 1980, The American journal of medicine.

[50]  A. Barrett,et al.  VP16-213 as a single agent in advanced testicular tumors. , 1980, European journal of cancer.

[51]  D. Hedley,et al.  Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan. , 1979, British Journal of Cancer.

[52]  A. Rowe.  Biochemical aspects of cryoprotective agents in freezing and thawing. , 1966, Cryobiology.